A phase 1B inpatient, randomized, double-blind, placebo-controlled, crossover study of the safety and efficacy of two fixed doses of PF-3463275 in adjunctive treatment of cognitive deficits in schizophrenia.

Trial Profile

A phase 1B inpatient, randomized, double-blind, placebo-controlled, crossover study of the safety and efficacy of two fixed doses of PF-3463275 in adjunctive treatment of cognitive deficits in schizophrenia.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2008

At a glance

  • Drugs PF 3463275 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top